Статья
Семейная гиперхолестеринемия: современное состояние проблемы и лечебно-профилактическая помощь
Семейная гиперхолестеринемия является наиболее распространенным наследственным заболеванием, характеризующимся повышением концентрации холестерина липопротеинов низкой плотности и преждевременным развитием сердечно-сосудистых заболеваний атеросклеротического генеза. Диагностика и лечение таких больных сопряжены с определенными трудностями. В данном обзоре приведены данные о распространенности семейной гиперхолестеринемии, рассмотрены особенности выявления больных с подобным диагнозом, профилактики неблагоприятных сердечно-сосудистых событий, обсуждены вопросы назначения гиполипидемической терапии.
1. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-90. doi:10.1093/eurheartj/eht273.
2. Akioyamen LE, Genest J, Shan SD, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open. 2017;9(7):e016461. doi:10.1136/bmjopen-2017-016461.
3. Ershova AI, Meshkov AN, Bazhan SS, et al. The prevalence of familial hypercholesterolemia in the West Siberian region of the Russian Federation: A substudy of the ESSE-RF. 2017;12(7):e0181148. doi:10.1371/journal.pone.0181148.
4. Nordestgaard BG, Benn M. Genetic testing for familial hyper-cholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world? Eur Heart J. 2017;38(20):1580-3. doi:10.1093/eurheartj/ehx136.
5. Goldstein JL, Brown MS. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem. 1974;249(16):5153-62.
6. Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholestero-laemia. Atherosclerosis. 1993;104(1-2):1-18. doi:10.1016/0021-9150(93)90171-p.
7. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154-6. doi:10.1038/ng1161.
8. Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160(5):407-20. doi:10.1093/aje/kwh236.
9. Harada-Shiba M, Takagi A, Miyamoto Y, et al. Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab. 2003;88(6):2541-7 doi:10.1210/jc.2002-021487.
10. Yamamoto T, Davis CG, Brown MS, et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell. 1984;39(1):27-38. doi:10.1016/0092-8674(84)90188-0.
11. Soutar AK, Naoumova R. P. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4(4):214-25. doi:10.1038/ncpcardio0836.
12. Hopkins PN, Defesche J, Fouchier SW, et al. Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circ Cardiovasc Genet. 2015;8(6):823-31. doi:10.1161/CIRCGENETICS.115.001129.
13. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease 8th ed. New York: McGraw-Hill, 2001:2863-913. ISBN 978-0-071-36321-1.
14. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):844-53. doi:10.1093/eurheartj/ehq386.
15. Kwiterovich PO, Fredrickson DS, Levy RI. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest. 1974;53(5):1237-49. doi:10.1172/JCI107670.
16. Langsted A, Kamstrup PR, Benn M, et al. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol. 2016;4(7):577-87 doi:10.1016/S2213-8587(16)30042-0.
17. Clarke R, Peden JF, Hopewell JC, et al. PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518-28. doi:10.1056/NEJMoa0902604.
18. Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55(19):2160-7 doi:10.1016/j.jacc.2009.10.080.
19. Kamstrup PR, Tybj®rg-Hansen A, Steffensen R, et al. Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction. JAMA. 2009;301(22):2331-9. doi:10.1001/jama.2009.801.
20. Akioyamen LE, Genest J, Chu A, et al. Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. J Clin Lipidol. 2019;13(1):15-30. doi:10.1016/j.jacl.2018.10.012.
21. Perez de Isla L, Alonso R, Mata N, et al. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017; 135(11 ):2133-2144. doi: 10.1161/CIRCULATIONAHA.116.024541.
22. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303(6807)893-6. doi:10.1136/bmj.303.6807.893.
23. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001;357(9251):165-8. doi:10.1016/S0140-6736(00)03587-X.
24. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72(2):171-6.
25. Wang J, Dron JS, Ban MR, et al. Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically. Arterioscler Thromb Vasc Biol. 2016;36(12):2439-45. doi:10.1161/ATVBAHA.116.308027
26. Hopkins PN, Lane SR. Genotype-guided diagnosis in familial hypercholesterolemia: clinical management and concerns. Curr Opin Lipidol. 2017;28(2): 144-51. doi: 10.1097/MOL.0000000000000397.
27. Marks D, Wonderling D, Thorogood M, et al. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2000;4(29):1-123. doi:10.3310/hta4290.
28. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455.
29. Perez de Isla L, Alonso R, Watts GF, et al. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry FollowUp. J Am Coll Cardiol. 2016;67(11):1278-85. doi: 10.1016/j.jacc.2016.01.008.
30. Garcia-Calvo M, Lisnock HG, Bull BE, et al. The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1) Proc Natl Acad Sci. 2005;102(23):8132-7 doi:10.1073/pnas.0500269102.
31. Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol. 2014;54:273-93. doi:10.1146/annurev-pharmtox-011613-140025.
32. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331-40. doi:10.1016/S0140-6736(14)61399-4.
33. Ginsberg HN, Rader DJ, Raal FJ, et al. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther. 2016;30(5)473-83. doi:10.1007/s10557-016-6685-y.
34. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996-3003. doi:10.1093/eurheartj/ehv370.
35. Kastelein JJ, Hovingh GK, Langslet G, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017;11(1):195-203. doi:10.1016/j.jacl.2016.12.004.
36. Robinson JG, Farnier M, Krempf M, et al. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489-99. doi:10.1056/NEJMoa1501031.
37. Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31(3):149-62. doi:10.1002/jca.21470.
38. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008;29(21):2625-33. doi: 10.1093/eurheartj/ehn422.
39. Besseling J, Hovingh GK, Huijgen R, et al. Statins in familial hypercholesterolemia: consequences for coronary artery disease and allcause mortality. J Am Coll Cardiol. 2016;68(3):252-60. doi:10.1016/j.jacc.2016.04.054.
40. Ежов М. В., Близнюк С. А., Тмоян Н. А. и др. Регистр пациентов с семейной гиперхолестеринемией и пациентов очень высокого сердечно-сосудистого риска с недостаточной эффективностью проводимой гиполипидемической терапии (РЕНЕССАНС). Российский кардиологический журнал. 2019;(5):7-13. doi:10.15829/1560-4071-2019-5-7-13.
41. Близнюк С. А., Рожкова Т.А., Ежов М. В., и др. Особенности гиполипидеми-ческой терапии и предикторы исходов у больных с семейной гиперхолестеринемией. Атеросклероз и дислипидемии. 2019;37(4):36-45. doi: 10.34687/2219-8202.JAD.2019.04.0004.
42. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430-40. doi:10.1056/NEJMoa1615758.
43. Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial. JAMA Cardiol. 2019;4(11):1067-75. doi:10.1001/jamacardio.2019.3502.
44. Jia X, Virani SS. CLEAR Serenity Trial: More Clarity for the Future of Bempedoic Acid in Patients Unable to Take Statins? J Am Heart Assoc. 2019;8(7):e012352. doi:10.1161/JAHA.119.012352.
45. Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380(11):1022-32. doi:10.1056/NEJMoa1803917